Strategic partnerships AQEMIA partners with top pharmaceutical companies and runs proprietary programs, presenting opportunities for co-development, licensing deals, and strategic collaborations in oncology and other major diseases.

Global expansion With offices in Paris and London and recent London's expansion on the horizon, there is a clear path for international client engagement, regional partnerships, and multi-market collaborations across Europe.

Tech-enabled discovery AQEMIA combines quantum-inspired physics with generative AI using a scalable tech stack (CUDA, AWS, Docker, NoSQL) to rapidly generate drug candidates, offering a compelling value proposition for pharma companies seeking faster, data-driven R&D.

Funding momentum Significant funding milestones and a growing revenue base signal financial robustness and scalability, enabling larger collaboration scopes, joint ventures, and milestone-driven deals.

Talent and growth Active hiring and participation in tech and biotech ecosystems (French Tech 120, BIA, Knowledge Quarter) indicate readiness to scale partnerships, co-investments, and customer-facing collaboration programs.